Mode
Text Size
Log in / Sign up
N/A N=91 Randomized Treatment

The Long-Term Treatment of Drug Addiction and Unemployment

Substance Abuse, Intravenous

Enrolled (actual)
91
Serious AEs
14.3%
Results posted
Aug 2022
Primary outcome: Primary: The Percentage of Opiate- and Cocaine-negative Urine Samples — 44.9; 64.6 percentage of urine samples — p=.05

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Abstinence-contingent wage supplements (Behavioral); Individual Placement and Support (IPS) supported employment (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Johns Hopkins University
Primary completion
Sep 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
The Percentage of Opiate- and Cocaine-negative Urine Samples
44.9; 64.6 .05
PRIMARY
The Percentage of Participants Who Are Employed
27.7; 59.1 .05
SECONDARY
The Percentage of Participants Who Report Injecting Drugs
SECONDARY
The Percentage of Participants Who Report Trading Unprotected Sex for Drugs or Money
SECONDARY
The Percentage of Participants Who Report Sharing Injection Equipment
SECONDARY
The Percentage of Participants With Household Incomes Below the Federal Poverty Level
SECONDARY
The Percentage of Opiate- and Cocaine-negative Urine Samples Post-intervention
SECONDARY
The Percentage of Participants Who Are Employed Post-intervention
SECONDARY
The Percentage of Participants Who Report Injecting Drugs Post-intervention
SECONDARY
The Percentage of Participants Who Report Trading Unprotected Sex for Drugs or Money Post-intervention
SECONDARY
The Percentage of Participants Who Report Sharing Injection Equipment Post-intervention

Summary

The purpose of this clinical trial is to evaluate the effectiveness and economic benefits of a Wage Supplement Model of arranging long-term exposure to employment-based abstinence reinforcement.

Eligibility Criteria

Inclusion Criteria

  • report heroin use

Exclusion Criteria

  • report current suicidal or homicidal ideation;
  • have a severe psychiatric disorder
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02487745). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search